BiotechTube

BGE-117

Phase 2Withdrawn
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anemia

Conditions

Anemia

Trial Timeline

Mar 22, 2021 → Apr 1, 2022

NCT ID
NCT04815603

About BGE-117

BGE-117 is a phase 2 stage product being developed by BioAge Labs for Anemia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04815603. Target conditions include Anemia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04815603Phase 2Withdrawn

Competing Products

20 competing products in Anemia

See all competitors
ProductCompanyStageHype Score
Aranesp®AmgenApproved
84
KER-047Keros TherapeuticsPhase 2
44
LY2787106Eli LillyPhase 1
33
R744 + R744Chugai PharmaceuticalPhase 3
77
epoetin beta + placeboChugai PharmaceuticalPhase 3
77
recombinant human erythropoietin + recombinant human erythropoietin placeboChugai PharmaceuticalPhase 3
77
recombinant human erythropoietin + recombinant human erythropoietinChugai PharmaceuticalPhase 3
77
darbepoetin alfaAmgenPhase 3
76
PrasugrelDaiichi SankyoPhase 1
33
Prasugrel + PlaceboDaiichi SankyoPhase 2
52
roxadustatAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
AlefaceptAstellas PharmaPhase 1
33
RoxadustatAstellas PharmaPhase 2
52
roxadustatAstellas PharmaPhase 1
33
Roxadustat + PlaceboAstellas PharmaPhase 3
77
RoxadustatAstellas PharmaPre-clinical
23
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
77
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77

Other Products from BioAge Labs

BGE-175Phase 2
47
BGE-117, 4mg + BGE-117, 12mgPhase 2
47
AzelapragPhase 1
28